Medicure has acquired the US rights to Aggrastat#174; Injection (tirofiban hydrochloride) from MGI PHARMA. In so doing, it has gained the opportunity to establish a sales and marketing capability in the cardiovascular market ahead of the anticipated launch of its lead pipeline candidate MC-1, a cardioprotective agent that is soon to start Phase III trials. Assuming that MC-1 is able to gain regulatory approval, the deal can be regarded as a positive move for Medicure. For MGI PHARMA, the transaction finally sees it rid itself of a long unwanted product that it acquired along with its US$178 M acquisition of Guilford Pharmaceuticals in June 2005. This article discusses the ramifications of the deal and the motivations of the companies involved.